Skip to content
Clinical Trials – home

Turner's syndrome Diagnostics

3 / 6 trials open to patients17 countries1 support organisation

In short

Turner syndrome diagnostics involve a range of tests that can identify this chromosomal condition at different stages of life, from before birth through adulthood. Understanding when and how testing is performed helps families and patients access timely treatment and support for managing the various health aspects associated with the condition.

Key points

  • Turner syndrome can be diagnosed at any stage from before birth through adulthood, with the timing depending on which symptoms appear first.
  • The definitive diagnostic test is karyotype analysis from a blood sample, which reveals whether one X chromosome is missing or abnormal.
  • Short stature and delayed or absent puberty are the most common symptoms that prompt diagnostic testing in childhood and adolescence.
  • Comprehensive screening for heart, kidney, thyroid, hearing, and bone health problems is essential at diagnosis and throughout life.
  • Prenatal diagnosis is possible through ultrasound findings followed by chorionic villus sampling or amniocentesis for chromosome analysis.
  • Heart defects affect up to half of individuals with Turner syndrome, making cardiovascular evaluation a critical diagnostic component.
  • Mosaic Turner syndrome, where only some cells have the chromosomal abnormality, often causes milder symptoms but requires the same diagnostic testing.
  • Early diagnosis enables timely treatment with growth hormone and hormone replacement therapy to improve height and development outcomes.

Introduction: Who Should Undergo Diagnostics

Turner syndrome can be identified at many different points in a person's life, and knowing when to seek diagnostic testing is important for ensuring early intervention and appropriate care. The timing of diagnosis varies widely, which means that healthcare providers need to remain alert to signs and symptoms that might suggest the condition at any age.

During pregnancy, diagnostic testing may be recommended if routine ultrasound scans reveal certain concerning features in the developing baby. These warning signs include an increased thickness at the back of the neck (called increased nuchal translucency), a fluid-filled sac on the neck (cystic hygroma), problems with the heart (especially on the left side), or issues with the kidneys. When these features appear on ultrasound, doctors may suggest further testing to confirm whether Turner syndrome is present.

At birth, certain physical characteristics may prompt healthcare providers to order diagnostic tests. Newborns with Turner syndrome might have swelling in their hands and feet, extra folds of skin on the neck (webbed neck), ears that are positioned lower than usual or shaped differently, a low hairline at the back of the head, or a broad chest with widely spaced nipples. If a doctor notices these features, they will typically recommend blood tests to check the baby's chromosomes.

During childhood, parents and doctors should consider Turner syndrome testing if a girl is growing much more slowly than her peers. Most girls with Turner syndrome will show noticeable differences in height by around age five, as they tend to be shorter than other children their age and may not experience the usual growth spurts that happen during childhood and adolescence. This lack of expected growth is often one of the first clear signs that prompts diagnostic testing.

In teenage years and young adulthood, diagnostic testing should be considered if a young woman does not begin puberty at the expected time or experiences primary amenorrhea (meaning she never starts having menstrual periods). Most girls typically begin developing breasts and start menstruation between ages 10 and 14, so if these milestones do not occur, healthcare providers should investigate the possibility of Turner syndrome. Some women are not diagnosed until adulthood, when they seek medical help because they are unable to become pregnant.

Diagnostic Methods

The definitive way to diagnose Turner syndrome involves analyzing a person's chromosomes through laboratory testing. The primary diagnostic test is called a karyotype analysis, which examines the chromosomes in a person's cells. Normally, females have two complete X chromosomes in each cell, but in Turner syndrome, one X chromosome is either completely missing or partially absent. The karyotype test can identify this chromosomal difference and confirm the diagnosis.

To perform a karyotype analysis, healthcare providers typically collect a blood sample from the patient. The blood contains cells that can be examined in a laboratory to count and assess the structure of the chromosomes. Sometimes, instead of blood, doctors may collect cells from the inside of the cheek (called a buccal smear) or take a small skin sample. The cells are then sent to a specialized genetics laboratory where technicians prepare and examine them under a microscope to create a detailed picture of the chromosomes.

There are different patterns that can be identified through karyotype testing. About half of girls with Turner syndrome have monosomy X, which means every cell in their body has only one X chromosome instead of two (written as 45,X). This is usually the more recognizable form of the condition with more obvious symptoms. Other girls have what is called mosaic Turner syndrome, where some cells have the normal two X chromosomes while other cells have only one X chromosome. Girls with mosaic Turner syndrome often have milder symptoms and may be more difficult to diagnose based on physical appearance alone.

In addition to confirming the diagnosis, doctors will perform other tests to assess the various health conditions that can occur alongside Turner syndrome. These screening tests help healthcare providers understand the full picture of a patient's health and identify any complications that need treatment or monitoring.

Heart evaluations are essential for all patients at the time of diagnosis. Doctors will perform a physical examination to listen to the heart and check blood pressure. An echocardiogram (an ultrasound of the heart) is typically ordered to look for structural problems with the heart, such as a narrowed aorta (the major blood vessel carrying blood from the heart), a bicuspid aortic valve (a valve with two flaps instead of the normal three), or other heart defects. About one-third to one-half of individuals with Turner syndrome are born with some type of heart problem, making cardiovascular screening a critical part of the diagnostic process.

Kidney assessment is also important because some people with Turner syndrome have kidney abnormalities. A kidney ultrasound or other imaging tests can reveal structural problems with the kidneys or urinary system that might not cause obvious symptoms but could affect health over time.

Hearing tests should be conducted as part of the diagnostic evaluation because hearing problems are more common in people with Turner syndrome. These may include recurrent ear infections that can lead to hearing loss, as well as sensorineural hearing loss (a type of hearing problem caused by damage to the inner ear or the nerve pathways to the brain). Regular hearing assessments help identify problems early so appropriate interventions can be implemented.

Eye examinations are recommended to check for vision problems and structural issues with the eyes, such as drooping eyelids or other features that might affect sight. Regular eye tests help ensure any vision problems are corrected with glasses or other treatments.

Thyroid function tests are important because individuals with Turner syndrome have an increased risk of developing thyroid problems. Blood tests can measure thyroid hormone levels and identify conditions like hypothyroidism (when the thyroid gland does not produce enough hormone), which can affect growth, development, and overall energy levels.

Bone density testing may be performed, especially in older children and adults, to assess bone strength. People with Turner syndrome are at higher risk for developing weak bones (osteoporosis), particularly if they have not received appropriate hormone replacement therapy.

Healthcare providers will also assess developmental and learning abilities. While most people with Turner syndrome have normal intelligence, some may experience specific learning challenges, particularly with spatial awareness, mathematics, and certain social skills. Psychological and educational assessments can help identify areas where additional support might be beneficial.

Prenatal Diagnostic Testing

When Turner syndrome is suspected before birth, two main procedures can be used to test the baby's chromosomes while the mother is still pregnant. These tests are more invasive than ultrasound and carry a small risk, so they are typically offered only when there is a specific reason to suspect a chromosomal condition.

Chorionic villus sampling (CVS) involves taking a small sample of tissue from the placenta, which is the organ that nourishes the developing baby. The placenta contains the same genetic material as the baby, so examining its cells can reveal whether Turner syndrome is present. This test is usually performed between 11 and 14 weeks of pregnancy. A doctor inserts a thin tube through the cervix or uses a needle through the abdomen to collect the tissue sample, which is then sent to a laboratory for chromosome analysis.

Amniocentesis is another prenatal testing option that involves collecting a sample of the amniotic fluid that surrounds the baby in the womb. The developing baby sheds cells into this fluid, and these cells can be examined to determine the baby's chromosomal makeup. Amniocentesis is typically performed after 14 weeks of pregnancy. During the procedure, a doctor uses ultrasound guidance to insert a thin needle through the mother's abdomen and into the amniotic sac to withdraw a small amount of fluid.

In recent years, newer screening tests have become available that analyze the baby's DNA circulating in the mother's bloodstream. These tests, called prenatal cell-free fetal DNA screening or noninvasive prenatal screening, can indicate an increased risk of Turner syndrome without requiring an invasive procedure. However, these screening tests cannot provide a definitive diagnosis, so if results suggest Turner syndrome, doctors will recommend confirmatory testing through CVS or amniocentesis.

Diagnostics for Clinical Trial Qualification

When individuals with Turner syndrome are being considered for participation in clinical trials, additional diagnostic criteria and tests may be required beyond those used for standard diagnosis. Clinical trials often have specific inclusion and exclusion criteria that help researchers ensure they are studying the condition in a consistent and scientifically valid way.

The fundamental requirement for clinical trial enrollment is confirmed diagnosis of Turner syndrome through karyotype analysis. Researchers typically require documentation showing the specific chromosomal abnormality, whether it is complete monosomy X (45,X) or a mosaic pattern. Some clinical trials may focus on specific chromosomal variants, so the exact karyotype results become important for determining eligibility.

For clinical trials studying growth hormone therapy, baseline measurements are essential. Researchers will document the participant's current height, weight, and growth velocity (how quickly they are growing over time). Bone age assessment, typically done through an X-ray of the left hand and wrist, helps determine skeletal maturity and predict remaining growth potential. Many trials require participants to be still growing, which means they cannot have reached full skeletal maturity (usually defined as a bone age of 14 years or less).

Cardiovascular assessment is typically required for clinical trial participation, particularly for trials involving hormone therapies. Detailed heart imaging, including echocardiography, helps identify any structural heart problems or aortic complications that might make certain treatments risky or inappropriate. Researchers need to document blood pressure readings and any history of cardiovascular issues.

Hormone level testing is crucial for trials examining puberty induction or fertility treatments. Blood tests measuring follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrogen, and other reproductive hormones help researchers understand ovarian function and determine appropriate treatment protocols. These baseline hormone levels also serve as comparison points to assess whether trial treatments are having the desired effects.

For trials examining specific health complications associated with Turner syndrome, additional specialized testing may be required. This could include detailed kidney function tests, comprehensive thyroid panels, hearing assessments, or cognitive and psychological evaluations depending on what the clinical trial is investigating.

Quality of life assessments and standardized questionnaires often form part of the diagnostic workup for clinical trial participation. These tools help researchers measure not only the physical effects of Turner syndrome but also the psychological, social, and emotional impacts, allowing them to evaluate whether interventions improve overall wellbeing alongside specific medical outcomes.

Prognosis and Survival Rate

Prognosis

The outlook for individuals with Turner syndrome has improved significantly with modern medical care and early intervention. Most girls and women with Turner syndrome can lead relatively normal, healthy, and productive lives with appropriate treatment and support. The condition affects each person differently, with some experiencing only mild symptoms while others face more significant health challenges.

Short stature is nearly universal in untreated Turner syndrome, with average adult height reaching about 143 centimeters (4 feet 8 inches). However, when growth hormone therapy is started early in childhood and continued for several years, many girls can achieve near-normal heights. The longest treatment durations before puberty typically result in the best height outcomes.

Fertility remains a significant challenge, as almost all women with Turner syndrome are infertile without medical assistance. The ovaries typically do not function normally, and most girls do not undergo spontaneous puberty. However, hormone replacement therapy can induce the physical changes of puberty, including breast development and menstruation. Some women with mosaic Turner syndrome may retain normal ovarian function through young adulthood, and advances in assisted reproductive technology, including egg donation and in vitro fertilization, have made pregnancy possible for some women with the condition.

The presence of heart defects significantly influences long-term prognosis. Individuals born with structural heart problems, particularly those affecting the aorta or heart valves, require careful monitoring throughout life. Progressive aortic root dilatation or dissection can occur, especially in patients with a bicuspid aortic valve, coarctation of the aorta, or untreated high blood pressure. Regular cardiac evaluations and early treatment of complications are essential for preventing serious cardiovascular events.

Other health conditions commonly associated with Turner syndrome can generally be managed effectively with appropriate medical care. Thyroid problems, hearing loss, kidney abnormalities, and bone health issues can all be monitored through regular screening and treated when necessary. Learning difficulties, when present, can be addressed through educational support and interventions tailored to the individual's needs.

Survival Rate

Turner syndrome can slightly reduce life expectancy compared to the general population, but with proper medical care and monitoring, most people with the condition live well into adulthood and beyond. The reduction in lifespan is primarily related to cardiovascular complications, which account for the majority of increased mortality risk in Turner syndrome.

Early diagnosis and comprehensive healthcare significantly improve outcomes. Regular health checks to monitor blood pressure, bone density, thyroid function, and cardiovascular health are essential for identifying and treating problems before they become serious. When heart defects are identified early and managed appropriately, the risk of life-threatening complications can be substantially reduced.

The condition affects approximately 1 in 2,000 to 2,500 live-born girls. However, Turner syndrome is much more common among pregnancies that do not survive to term. It has been estimated that only about 1 percent of fetuses with monosomy X survive to birth, and as many as 10 percent of first-trimester miscarriages involve this chromosomal abnormality. This means that Turner syndrome is significantly more lethal during fetal development than after birth.

With advances in medical treatment, ongoing multidisciplinary care, and well-planned transitions from pediatric to adult healthcare services, individuals with Turner syndrome can achieve their full potential and enjoy a good quality of life. The key to the best possible outcomes lies in early diagnosis, proactive screening for associated health conditions, timely treatment interventions, and comprehensive long-term follow-up care.

Did you know?

  1. Turner syndrome causes approximately 10% of all first-trimester miscarriages, with only 1% of affected fetuses surviving to birth, making it far more common in early pregnancy than among newborns.
  2. Some women with mosaic Turner syndrome have such mild symptoms that they are not diagnosed until adulthood when investigating infertility, showing that the condition can hide in plain sight for decades.
  3. A simple hand X-ray can reveal "bone age" to help predict remaining growth potential and guide treatment timing, as the bones in the hand mature in predictable patterns that doctors can compare to chronological age.

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Turner's syndrome

Recruiting trials first

See all 6 trials →
Quick filters

6 clinical trials in this condition

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · Healthy volunteers
  • Substances:Estradiol
  • Sponsor:Region Midtjylland
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:CARBOMER 980
  • Sponsor:Region Midtjylland
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Vosoritide
  • Sponsor:Biomarin Pharmaceutical Inc.
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S
See all 6 trials →filters applied: condition = Turner's syndrome

Where to find support

Patient organisations offering help, community and advocacy

Related conditions in the same therapeutic area

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).